ERBB2 and neoplasm: Notably, the most evident differences emerged from the comparison between the two groups of patients, with HER2- cases showing significantly reduced levels of IL-2 (P = 0.0229), IL-1β (P = 0.0207), IL-8 (P = 0.007), IL-6 (P = 0.0001), and IL-10 (P = 0.0247; Figure 4), independently by other clinical-pathological parameters such as HR expression and tumor grading (P-trend in multivariate analysis: IL-1β P = 0.002, IL-2 P = 0.004, IL-6 P = 0.004, IL-8 P = 0.02, IL-10 P = 0.02; Table 3).